摘要
目的:评价雷帕霉素(RPM)口服液联合环孢素(CsA)预防肾移植术后早期急性排斥反应的疗效。方法:首次肾移植患者20例,随机分成RPM试验组和硫唑嘌呤(Aza)对照组,每组各10例,分别接受以CsA和类固醇激素为基础的免疫抑制治疗方案6mo,比较2组人/肾存活率、急性排斥反应发生、不良事件发生等指标的差异。结果:17例完成治疗者人/肾均存活;仅Aza组1例发生2次急性排斥反应;2组各发生2例严重不良事件。结论:RPM联合CsA可有效预防移植肾急性排斥反应,并维持肾功能于良好水平,但是也可能增强CsA的肝毒性。
OBJECTIVES： To evaluate the efficacy of rapamycin（RPM） oral liquid plus cyclosporine（CsA） on the preven tion of early acute rejection after renal allograft .METHODS： 20 patients undergoing primary renal allografting were randomly divided into RPM trial group and Azathioprlne（Aza） control group, 10 cases in each group, who were respectively assigned to receive CsA and adrenocortial hormones- based immunosuppression for 6 months,indexes including survival rates of recipients/ kidneys, incidences of acute rejection and adverse reactions between 2 groups were compared .RESULTS： For the 17 patients who had finished 6-month treatment, the survival rates（recipients/ kidneys） were 100% .Only 2 episodes of acute rejection occurred in one case in Aza group .Both groups had 2 cases of severe adverse episodes.CONCLUSIONS： The combined therapy pf RPM plus CsA is effective in the prevention of acute renal allograft rejection, and it can maintain renal function at a good level.Nevertheless,it may increase the hepatotoxicity of CsA.
出处
《中国药房》
CAS
CSCD
北大核心
2006年第13期1002-1004,共3页
China Pharmacy
关键词
雷帕霉素
硫唑嘌呤
环孢素
肾移植
免疫抑制
排斥反应
Rapamycin
Azathioprine
Ciclosporin
Renal transplantation
Immunosuppress
Rejection
